550PUpdated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer

ConclusionsCet every two weeks in combination with FOLFIRI or alternating FOLFIRI/FOLFOX is well tolerated with high RR and long OS. We recommend FOLFIRI + cet every 2 weeks in patients with RAS and BRAFwt mCRC.Clinical trial identification2011-004188-65.Legal entity responsible for the studyNordic Biomodulation Group.FundingMerck.DisclosureC. Kersten: Research grant / Funding (institution), Licensing / Royalties, Relationship is unrelated to this study: Merck KGaA. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

AbstractBackgroundThe orally administered combination trifluridine and tipiracil hydrochloride (TAS-102) has been approved as third line treatment in metastatic colorectal cancer, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study.MethodsWe performed an updated multicentre retrospective observational study of patients with metastatic colorectal cancer, receiving TAS-102 as third line treatment between 2016 and 2019 in 8 cancer centers across the UK. Medical records were reviewed for clinicopathological characteristics, treatment, survival and toxicity outcomes. Prognostic and pre...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 11 April 2019Source: Inorganica Chimica ActaAuthor(s): Irene S. Um, Evangeline Armstrong-Gordon, Yvonne E. Moussa, Danijela Gnjidic, Nial J. WheateAbstractA cross-sectional descriptive study in Australia was undertaken to examine the current clinical guidelines on the use of platinum-based drugs in cancer treatment. From the Australian EviQ system, data from each chemotherapy protocol was collected with respect to recommended drugs for specific cancer types, drug doses, and dose modifications. Only three drugs have marketing approval: cisplatin, carboplatin, and oxaliplatin, and they are ...
Source: Inorganica Chimica Acta - Category: Chemistry Source Type: research
We describe the overall safety and tolerability profiles based on a literature review of all published phase I and II clinical trials in this setting. Drug exposure, tumour mutational status and metastases resectability are discussed. A review of pubmed and abstracts of major oncology congresses from 2009 to 2018, with MeSH and full-text search terms for clinical trials of anti-EGFR for "metastatic" or "advanced" "colorectal cancer/adenocarcinoma" was implemented. Only English language publications were included. Expert opinion: Efficacy data from phase II trials are promising, but the safety ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
CONCLUSIONS: Patients with XELOX scheme referred to have worse  emotionally status in the middle of the adjuvant treatment than patients  treated with FOLFOX scheme and presented a worsening in items fatigue,  nausea, vomiting, anorexia and diarrhoea. PMID: 30848178 [PubMed - in process]
Source: Farmacia Hospitalaria - Category: Drugs & Pharmacology Authors: Tags: Farm Hosp Source Type: research
CONCLUSION: The modification of the FOLFIRI regimen impacted treatment response of mCRC patients. The addition of an antiangiogenic agent, in particular aflibercept, enhanced the clinical benefit and improved survival. PMID: 30815374 [PubMed]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: World J Clin Oncol Source Type: research
CONCLUSIONS: Based on a limited number of trials, very sparse data, and uncertainty of the evidence, this review was unable to establish whether there was a difference in overall survival or other clinically relevant outcomes, between immediate or delayed chemotherapy in persons with metastatic, incurable, colorectal cancer. The results should be interpreted with caution. PMID: 30480771 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Cancer-related cachexia is a disorder characterized by loss of body weight with specific losses of skeletal muscle and adipose tissue. Cachexia is driven by a variable combination of reduced food intake and metabolic changes, including elevated energy expenditure, excess catabolism and inflammation [1]. The development of cancer cachexia is common in people with solid tumors such as pancreatic, lung, gastric and colorectal cancer. Weight loss and malnutrition are observed frequently in patients with cancer cachexia, especially for cancer patients after surgery (malabsorption), radiotherapy (nausea, pain, diarrhoea, mucosit...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: General and Supportive Care Source Type: research
ConclusionsWe confirm that UGT1A1*37 and UGT1A1*28 are associated with severe toxicity and suggest that the CYP3A4*20 allele does not play a role in irinotecan‐induced toxicity.
Source: British Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: SHORT REPORT Source Type: research
CONCLUSIONS: Results of this review should provide confidence that treatment for CRC with most of the oral fluoropyrimidines commonly used in current clinical practice is similarly efficacious to treatment with IV fluoropyrimidines. Treatment with eniluracil with oral 5-FU was associated with inferior PFS and OS among participants treated with palliative intent for CRC, and eniluracil is no longer being developed. Oral and IV fluoropyrimidines have different patterns of side effects; future research may focus on determining the basis for these differences. PMID: 28752564 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
This study aimed to investigate the prophylactic efficacy of Polaprezinc administered orally against intestinal mucositis induced by 5‐FU in mice on the condition that the anti‐tumour effect could not be compromised. We induced intestinal mucositis in SPF grade ICR mice with 5‐FU, and evaluated intestinal damage in the absence or presence of Polaprezinc. We examined the score of diarrhoea and the loss of weight following the 5‐FU treatment, and assessed the integrity of villus and the proliferation of small intestine crypt cells by Hematoxylin&Eosin staining and PCNA immunohistochemical detection. The anti‐tumour...
Source: Basic and Clinical Pharmacology and Toxicology - Category: Drugs & Pharmacology Authors: Tags: Original Article Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colorectal Cancer | Diarrhoea | Erbitux | Grants | Legislation | Merck | Neurology | Study | Toxicology